Introduction {#S0001}
============

Morphea (localized scleroderma) is a rare cutaneous disease characterized by two consecutive, inflammatory and sclerotic phases. Additionally, after some time, many patients show spontaneous skin softening, clinically manifested as atrophy with depigmentation \[[@CIT0001], [@CIT0002]\]. Although skin hardening is the prominent clinical symptom (which is at the same time the reason for disease classification as "scleroderma"), the clinical picture as well as immunologic abnormalities differ from the ones observed in systemic scleroderma \[[@CIT0001]--[@CIT0008]\]. Unfortunately, the disorder being rare, clinically diversified and potentially spontaneously reversible leads to the fact that its pathogenesis remains unknown, leaving no undoubtedly proven successful therapy \[[@CIT0009], [@CIT0010]\].

There are three known isoforms of transforming growth factor-β (TGF-β), i.e. TGF-β1, TGF-β2 and TGF-β3, all synthesized as inactive pro-peptides. The cytokine is multi-functional, yet it is believed to be the leading profibrotic factor in sclerotic disorders \[[@CIT0011]--[@CIT0013]\]. It interacts with extracellular matrix components, including fibrillin-1. Interestingly, a defective fibrillin-1 coding gene (FBN1) is the characteristic of the SSc -- Tsk1/+ murine model, while a mutation of this gene has been found in a group of native Americans, in which the risk of developing SSc is higher \[[@CIT0014]\]. Almost 30% of morphea patients show the presence of anti-fibrillin-1 antibodies \[[@CIT0015]\]. The activation of TGF-β is mediated by thrombospondin, plasmin, integrins and THY-1 (CD90), as well as matrix metalloprotease 9. Not only is TGF-β believed to initiate the production of extracellular matrix components (including collagen, fibronectin and proteoglycans) but also it inhibits their degradation due to interactions with matrix metalloproteinases and stimulation of synthesis of their inhibitors \[[@CIT0012], [@CIT0016], [@CIT0017]\]. It has been shown that TGF-β increases fibroblast susceptibility for apoptosis \[[@CIT0018]\]. There are other, numerous *in vitro* and *in vivo* studies acknowledging the role of TGF-β in fibrotic diseases. Indirectly, the role of TGF-β in morphea may be underlined by a case study of a patient in whom tyrosine kinase blocking (through which TGF-β mediates a Smad-independent intracellular signal) resulted in an improvement of the clinical condition \[[@CIT0019]\]. Yet, the role of TGF-β in morphea remains unclear, while the results of scientific studies do vary greatly.

Aim {#S0002}
===

The goal of this study was to estimate the expression level of *TGFB1* in skin and peripheral blood mononuclear cells (PBMC) as well as the plasma levels of TGF-β1 in plaque morphea (MEP).

Material and methods {#S0003}
====================

Material {#S20004}
--------

The study involved 20 MEP patients (10 women and 10 men). The mean age was 43 years, minimum 16, maximum 81, standard deviation (SD) = 19. The mean disease duration was 3.4 years (minimum 1, maximum 20, SD = 4). All patients were diagnosed both clinically and histopathologically. Whole blood samples were acquired from all patients, while 13 of them additionally were the source of skin biopsies. Three control groups were involved: 1 -- plasma: 36 healthy volunteers (29 women, 7 men), mean age was 34 years, minimum 20, maximum 57, SD = 9; 2 -- PBMC: 47 healthy volunteers (35 women, 12 men), mean age was 33, minimum 20, maximum 57, SD = 9; 3 -- skin biopsies: 13 samples collected during mastectomy. The neoplasms were not skin related. Mean age was 52 years, minimum 30, maximum 85, SD = 17. The study was approved by a local bioethical committee. All patients gave written consent. EDTA-collected whole blood samples (5 ml) were spun in ficoll gradient (Ficoll-Histopaque 1.077 g/cm^3^, Sigma Diagnostics, Inc. St. Louis, USA). Plasma samples were stored at --80°C. Upon collection, skin samples were immediately frozen in liquid nitrogen and stored at --80°C.

Methods {#S20005}
-------

### Evaluation of activity of the disease

A patient was qualified to the active process group, if within recent 6 months there had been an appearance of a new lesion, spread of a previously existing one or a presence of erythematous margins \[[@CIT0020], [@CIT0021]\].

### ELISA

The assessment of TGF-β1 protein plasma level was done with the use of a commercially available kit according to the manufacturer\'s instructions (R&D System, Minneapolis, USA).

### Real-time polymerase chain reaction assessment of transforming growth factor-β1 expression in peripheral blood mononuclear cells

Whole RNA samples were isolated from PBMC according to Chomczynski and Sacchi protocol \[[@CIT0022]\]. Genomic DNA from 1 µg RNA samples was removed with the use of a recombined DNase I (Ambion, USA). Following reverse transcription (Roche Applied Science), cDNA samples were analyzed with the use of real-time PCR in relative analysis mode with standard curves. The analysis was performed with the use of Light Cycler 2.0 thermocycler (Roche Diagnostics GmbH, Germany) and a dedicated commercial SYBR Green kit (Roche Applied Science).

The amplified cDNA fragment was 81 bp long. The sequence covered fragments of exons 4 and 5 of the TGF-β1 gene, spanning a 139 bp long intron, which due to short elongation time, minimized the chances of genomic DNA amplification. All RNA samples were subjected to no-RT PCR reactions for genomic DNA contamination analysis. PCR primer sequences, presented in [Table 1](#T0001){ref-type="table"}, were acquired from other studies \[[@CIT0023], [@CIT0024]\]. The quantitative results are expressed in *TGFB1* copy number for one million reference gene copies. Glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH) was chosen as a reference. The choice of this particular gene had been suggested in literature \[[@CIT0025]\].

###### 

Primers used in this study

  Name      5'-3\'sequence            Amplicon length \[bp\]   References
  --------- ------------------------- ------------------------ --------------------------------------------------------------------------------------------------------------------------------------
  GAPDH-F   CTGCACCACCAACTGCTTAG      105                      Ensembl: ENST00000229239 Glyceraldehyde-3-phosphate dehydrogenase \[[@CIT0023]\]
  GAPDH-R   TTCTGGGTGGCAGTGATG                                 
  TGFB1-F   GTGACAGCAGGGATAACACACTG   81                       Ensembl: ENST00000221930 Transforming growth factor, beta1 <http://www.rtprimerdb.org/assay_report.php?assay_id=1005> \[[@CIT0024]\]
  TGFB1-R   CATGAATGGTGGCCAGGTC                                

### Real-time polymerase chain reaction assessment of TGFB1 expression in skin

Skin samples stored at --80°C were rotor-stator homogenized in TriPure reagent (Roche Applied Science). Due to the high level of impurities, phenol-chloroform extraction was doubled and separated with successive isopropanol, 75% ethanol washings and the removal of genomic DNA. The remaining steps of the procedure were the same as for PBMC samples.

Statistical analysis {#S20010}
--------------------

Arithmetical means and SD values were calculated for age and disease duration. Additionally, the analysis of other variables included median, as well as minimum and maximum values due to lack of normal distribution. The statistical significance of differences was calculated with the use of the two independent Mann-Whitney-Wilcoxon test, while correlation analyses were performed with the Spearman\'s rank approach. Analyses were considered significant below *p* = 0.05 value.

Results {#S0011}
=======

The median expression level values of *TGFB1* in PBMC and skin as well as plasma TGF-β1 levels are presented in [Table 2](#T0002){ref-type="table"}. No statistically significant differences have been found for these variables between the groups of MEP and controls.

###### 

Expression of TGFB1 in PBMC, skin and plasma TGF-β1 level

  Variable                                                     MEP        Control groups   Value of *p*            
  ------------------------------------------------------------ ---------- ---------------- -------------- -------- --------
  Expression of TGFβ1 in *PBMC* (per million *GAPDH* copies)   *n* = 20   *n* = 47         0.9                     
  218674                                                       136538     574074           217453         108746   513292
  Plasma TGF-β1 level \[pg/ml\]                                *n* = 20   *n* = 36         0.4                     
  159                                                          32         1131             180            40       730
  Expression of *TGFβ1* in skin (per million *GAPDH* copies)   *n* = 13   *n* = 13         0.8                     
  29503                                                        10067      77760            32090          19469    83284

None of the analyzed variables (expression of *TGFB1* in PBMC, plasma TGF-β1 level and expression of *TGFB1* in skin) correlated with the disease duration. Ten MEP patients (50%) were assigned to the group with the active process. There were no statistically significant differences between active and non-active process groups with respect to the three aforementioned variables ([Table 3](#T0003){ref-type="table"}).

###### 

Expression of TGFB1 in PBMC, skin and plasma TGF-β1 level comparing the active and non-active process groups

  Variable                                                     MEP active process   MEP non-active   Value of *p*            
  ------------------------------------------------------------ -------------------- ---------------- -------------- -------- --------
  Expression of *TGFβ1* in PBMC (per million *GAPDH* copies)   *n* = 10             *n* = 10         0.3                     
  231408                                                       139216               574074           218674         136538   276142
  Plasma *TGF-β1* level \[pg/ml\]                              *n* = 10             *n* = 10         0.05                    
  250                                                          33                   1131             70             32       466
  Expression of *TGF-β1* in skin (per million GAPDH copies)    *n* = 8              *n* = 5          0.5                     
  31906                                                        23431                62500            21504          10067    77760

Discussion {#S0012}
==========

Although TGF-β is thought to be the main profibrotic cytokine, its possible contribution to the pathogenesis of morphea remains a matter of debate as the results of scientific studies concerning the subject contradict each other. Higley *et al*. detected elevated TGF-β1 levels in skin of morphea patients compared to healthy controls. Elevated TGF-β1 serum levels were detected in 8 out of 15 morphea patients (53%) compared to 2 out of 31 healthy controls (7%) \[[@CIT0026]\]. Similarly, elevated TGF-β in morphea patients was also detected by Uziel *et al*. and Lipko-Godlewska \[[@CIT0021], [@CIT0027]\]. On the other hand, Querfeld *et al*. found up-regulated *TGF*β1, β2 and β3 mRNA production only during the inflammatory phase of morphea, but not in the latter sclerotic one. These results were also supported by immunohistochemical analysis, yet the study involved only 2 patients with morphea in its inflammatory phase and only 1 in the sclerotic phase \[[@CIT0028]\]. Farell *et al*. presented the results of their study where they had found increased intensities of anti-TGF-β1, anti-TGF-β2, but not anti-TGFβ3 antibody staining in the upper and middle layers of the dermis of 2 morphea patients compared to healthy skin of labia \[[@CIT0029]\]. Kawakami *et al*. found that skin of deep morphea is more immunoreactive to anti-TGF-β3 \[[@CIT0030]\]. El-Mofty *et al*. claimed that a group of 21 morphea patients treated with UVA phototherapy showed a statistically significant down-regulation of *TGFB1* expression compared to the levels detected before the treatment. What is more, the change in *TGFB1* expression correlated with the effectiveness of the UVA treatment \[[@CIT0031]\]. This study, however, should be approached with caution as the RNA was isolated from paraffin-embedded skin. Such procedure may cause RNA degradation, resulting in a substantially lowered PCR sensitivity \[[@CIT0032], [@CIT0033]\]. Additionally, the quantitative assessment technique presented in this study is less precise than relative real-time PCR analysis.

In opposition to the aforementioned results, Restrepo *et al*. did not find differences in anti-TGF-β1 or in anti-TGF-β2 immunohistochemical staining between 10 linear morphea patients and 2 healthy individuals \[[@CIT0034]\]. Concordantly, Antiga *et al*. showed even a decrease in TGF-β+ cells in morphea skin compared to healthy controls and a decreased level of this protein in the studied sera \[[@CIT0035]\]. On the other hand, Kubo *et al*. assessed 5 morphea skin biopsies (2 -- MEP, 1 -- generalized morphea, 2 -- linear morphea) using in situ hybridization and found elevated expression levels of TGF-β type I and II receptors, predominantly in fibroblasts of the dermis, which was further supported by immunohistochemical staining \[[@CIT0036]\]. In our study we have not detected differences in *TGFB1* expression in PBMC, skin, or in plasma levels of TGF-β1 between MEP patients and healthy controls.

The reason for such incomparable results of these studies may be a significant diversity of the disease itself. Some of the authors, interestingly, did not include the relevant subtype of morphea, which might be of some importance regarding their results. On top of that, many of these studies, usually the older ones, involved only a few samples, which significantly decreases their credibility \[[@CIT0026], [@CIT0028], [@CIT0029]\]. However, many authors underlined that TGF-β could play a significant role especially during the initial, inflammatory phase \[[@CIT0010]--[@CIT0012], [@CIT0026]\], thus the moment of biopsy acquisition might have had an impact on the results. Yet, we have not observed any correlation between *TGFB1* in skin, PBMC or plasma TGF-β1 levels and disease duration, while it is important to note that 45% of our group suffered from morphea for less than a year, and the following 25% -- less than 2 years. Similar conclusions were suggested by Restrepo *et al*. \[[@CIT0034]\]. What is more, regardless of the disease duration, we have not detected relevant differences between active and non-active morphea patients. Antiga *et al*. indicate a potential role of T regulatory lymphocytes in the autoimmunization process in morphea. These lymphocytes are a significant source of TGF-β and their activity results in the phenomenon of tolerance. The decrease in their numbers or their impaired activity may lead to the induction of autoimmunization. During their biopsy studies, Antiga *et al*. found a lowered number of these cells, along with a decreased TGF-β1 levels in sera as well as fewer TGF-β+ cells in skin of morphea patients compared to psoriatic patients and healthy controls \[[@CIT0035]\].

While discussing these results, a failure of a clinical study involving a CAT-125 monoclonal anti-TGF-β1 antibody therapy in SSc is worth noting. The study not only did not confirm the effectiveness of this drug, but also the side effects were more frequent, including 3 deaths (caused by disease complications) compared to the placebo group (no patient died). The most frequent side effect, leading to the elimination of patients from the clinical phase, was a progression of skin involvement. However, there were no statistically significant differences between the studied groups assessed with the use of the modified Rodnan skin thickness score during all study stages. All groups showed improvement that was correlated with disease duration. At the same time, elevated TGF-β1 expression was found in patients before treatment initiation and tended to remain that way during the treatment. Finally, authors postulated the use of TGF-β pathways blocking agents instead \[[@CIT0037]\]. Imatinib is a tyrosine kinase inhibitor, registered as an anti-cancer (preferably as anti-lymphoproliferative neoplasms) drug. The kinases in question are a part of a Smad-independent pathway induced by TGF-β \[[@CIT0038]\]. There were two clinical studies involving Imatinib in SSc. One of them was prematurely ceased due to side effects \[[@CIT0039]\]. The other resulted in no improvement assessed with the modified Rodnan skin thickness score and diffusion capacity for carbon monoxide after 6 months of treatment \[[@CIT0040]\]. To date, the effectiveness of direct TGF-β blocking or any inhibition of its signaling pathways have not been confirmed, yet there has been a report on a morphea patient clinically responding well to Imatinib \[[@CIT0019]\].

Conclusions {#S0013}
===========

Our study was directed to the assessment of the influence of TGF-β1 in the pathogenesis of MEP. The results have not shown significant differences in *TGFB1* gene expression in PBMC and skin, as well as in plasma TGF-β1 levels between MEP patients and healthy controls, disease activity status or significant correlation with the disease duration. We are aware however of certain limitations of our study. It was only directed towards TGF-β1, leaving TGF-β2, TGF-β3 and their receptors without analysis. Additionally, the choice of the *GAPDH* as a reference gene for fibrotic skin assessment remains to be analyzed. The lack of convincing evidence concerning this and other possible reference genes for fibrotic skin is a problem. Generally speaking though, the results of our study contradict the claim of the substantial role of TGF-β1 in the most common morphea subtype -- MEP, which was also the conclusion of the study by Restrepo *et al*. \[[@CIT0034]\] and indirectly supported by the results of anti-TGF-β clinical studies in SSc \[[@CIT0037], [@CIT0039], [@CIT0040]\].
